MA41785A - Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques - Google Patents

Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques

Info

Publication number
MA41785A
MA41785A MA041785A MA41785A MA41785A MA 41785 A MA41785 A MA 41785A MA 041785 A MA041785 A MA 041785A MA 41785 A MA41785 A MA 41785A MA 41785 A MA41785 A MA 41785A
Authority
MA
Morocco
Prior art keywords
fumarates
compositions
treatment
methods
intravenous administration
Prior art date
Application number
MA041785A
Other languages
English (en)
Inventor
Shyam Karki
Robert Scannevin
Ajay Verma
Fengmei Zheng
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MA41785A publication Critical patent/MA41785A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225Polycarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/695Silicon compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
MA041785A 2015-03-20 2016-03-17 Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques MA41785A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562136431P 2015-03-20 2015-03-20

Publications (1)

Publication Number Publication Date
MA41785A true MA41785A (fr) 2018-01-23

Family

ID=55702079

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041785A MA41785A (fr) 2015-03-20 2016-03-17 Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques

Country Status (15)

Country Link
US (1) US20180289655A1 (fr)
EP (1) EP3270895A2 (fr)
JP (1) JP2018508559A (fr)
KR (1) KR20170138437A (fr)
CN (1) CN107666905A (fr)
AR (1) AR104029A1 (fr)
AU (1) AU2016235743A1 (fr)
CA (1) CA2979544A1 (fr)
EA (1) EA201792076A1 (fr)
HK (1) HK1244680A1 (fr)
IL (1) IL254576A0 (fr)
MA (1) MA41785A (fr)
MX (1) MX2017012239A (fr)
TW (1) TW201642847A (fr)
WO (1) WO2016153957A2 (fr)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
DE19721099C2 (de) 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
ES2297461T3 (es) * 2003-09-09 2008-05-01 Fumapharm Ag Uso de derivados del acido fumarico para tratar la insuficiencia cardiaca y el asma.
CA2478458A1 (fr) 2004-08-20 2006-02-20 Michael Panzara Traitement de la sclerose en plaques pediatrique
ES2523796T1 (es) * 2004-10-08 2014-12-01 Forward Pharma A/S Composición farmacéutica de liberación controlada que comprende éster de ácido fumárico
EP1940382A2 (fr) 2005-10-07 2008-07-09 Aditech Pharma AB Polytherapie a base d' esters d' acide fumarique pour le traitement de maladies autoimmunes et/ou inflammatoires
US20080089861A1 (en) 2006-07-10 2008-04-17 Went Gregory T Combination therapy for treatment of demyelinating conditions
EP2139467B1 (fr) * 2007-02-08 2016-09-21 Biogen MA Inc. Neuroprotection dans des maladies démyélinisantes
US20110112196A1 (en) * 2007-02-08 2011-05-12 Matvey E Lukashev Nrf2 screening assays and related methods and compositions
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
ES2477884T3 (es) 2008-08-19 2014-07-18 Xenoport, Inc. Profármacos de hidrogenofumarato de metilo, composiciones farmacéuticas de los mismos y procedimientos de uso
JP2012525385A (ja) 2009-04-29 2012-10-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 神経変性および神経炎症の治療
ME02317B (me) 2010-02-12 2016-06-20 Biogen Ma Inc Neuroprotekcija kod demijelinizacijskih bolesti
JP5072128B2 (ja) * 2011-03-31 2012-11-14 株式会社ワコール カップ部を有する衣類
WO2013022882A1 (fr) 2011-08-08 2013-02-14 The Board Of Trustees Of The Leland Stanford Junior University Polythérapie pour le traitement de maladie inflammatoire de démyélinisation
US9421273B2 (en) * 2011-12-16 2016-08-23 Biogen Ma Inc. Silicon-containing fumaric acid esters
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
SG11201404705YA (en) 2012-02-07 2014-10-30 Biogen Idec Inc Pharmaceutical compositions containing dimethyl fumarate
US20140057918A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Methods of Use for Monomethyl Fumarate and Prodrugs Thereof
WO2014096425A2 (fr) 2012-12-21 2014-06-26 Ratiopharm Gmbh Promédicaments de fumarate de monométhyle (mmf)
ES2733961T3 (es) 2012-12-21 2019-12-03 Biogen Ma Inc Derivados de fumarato sustituidos con deuterio
CN105163730B (zh) 2013-01-08 2018-10-30 帕萨罗杰卡有限公司 用于治疗脱髓鞘疾病的方法和组合物
WO2014138298A1 (fr) 2013-03-05 2014-09-12 University Of Chicago Traitement de troubles de démyélinisation
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US20150079180A1 (en) * 2013-09-18 2015-03-19 Xenoport, Inc. Nanoparticle compositions of dimethyl fumarate
CN103768045B (zh) * 2013-10-30 2015-10-07 苏州大学附属第一医院 富马酸二甲酯在制备治疗蛛网膜下腔出血后早期脑损伤药物的应用
WO2016074684A1 (fr) * 2014-11-11 2016-05-19 Syddansk Universitet Dérivés d'acide fumarique à usage médical

Also Published As

Publication number Publication date
JP2018508559A (ja) 2018-03-29
AR104029A1 (es) 2017-06-21
AU2016235743A1 (en) 2017-10-12
WO2016153957A3 (fr) 2016-11-10
TW201642847A (zh) 2016-12-16
EA201792076A1 (ru) 2018-04-30
HK1244680A1 (zh) 2018-08-17
US20180289655A1 (en) 2018-10-11
MX2017012239A (es) 2018-06-27
WO2016153957A2 (fr) 2016-09-29
CN107666905A (zh) 2018-02-06
KR20170138437A (ko) 2017-12-15
IL254576A0 (en) 2017-11-30
EP3270895A2 (fr) 2018-01-24
CA2979544A1 (fr) 2016-09-29

Similar Documents

Publication Publication Date Title
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
FR23C1008I2 (fr) Compositions d'arni de transthyretine (ttr) et procedes pour les utiliser pour le traitement ou la prevention de maladies associees a ttr
IL298689B1 (en) Preparations and methods for suppressing masp-3 for the treatment of various diseases and conditions
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA55629A (fr) Compositions d'anticorps pour le traitement de tumeurs
MA43283A (fr) Procédés et compositions pour le traitement du cancer
IL255109A0 (en) New dihydropyridoisoquinolinones and their pharmaceutical preparations for the treatment of inflammatory disorders
MA44875A (fr) Compositions pour le traitement de troubles acido-basiques
MA50849A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
MA56412A (fr) Thérapie par l'arn messager pour le traitement des maladies articulaires
MA42953A (fr) Composés et compositions pour le traitement de troubles oculaires
ZA202006234B (en) Compositions and methods for the treatment of neurological diseases
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
MA44700A (fr) Combinaison d'un anticorps anti-il-10 et d'un oligonucléotide de type cpg-c pour le traitement du cancer
FR3017298B1 (fr) Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
IL264070A (en) Methods and preparations for the treatment of disorders and diseases involving rdh12
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
MA43848A (fr) Composés deutérés pour le traitement d'hémopathies malignes, compositions et procédés associés
MA41432A (fr) Composition pharmaceutique pour le traitement de maladies gastro-intestinales
MA41785A (fr) Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques
FR3031112B1 (fr) Construction d'adn pour le traitement de pathologies oculaires
MA54511A (fr) Composition ophtalmique nutraceutique pour le traitement de pathologies retiniennes a composante neovasculaire
FR3017536B1 (fr) Compositions pour la prevention et/ou le traitement de pathologies liees a l'alpha-glucosidase